List of works - Alessandro Pancrazzi

A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF- 1 in the development of myelofibrosis

article

A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction.

scientific article published on 31 July 2008

Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis

scientific article

Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms

scientific article published on 10 April 2013

Anaemia characterises patients with myelofibrosis harbouring Mpl mutation.

scientific article published in May 2007

B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis.

scientific article

CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients

scientific article

CXCR4-independent rescue of the myeloproliferative defect of the Gata1low myelofibrosis mouse model by Aplidin

scientific article

Clonal architecture of JAK2V617F mutated cells during treatment with ruxolitinib.

scientific article

Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group

scientific article published on 2 April 2016

Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM090

scientific article published on 17 July 2013

Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis

scientific article published on 03 June 2010

Growth inhibition and differentiation of human breast cancer cells by the PAFR antagonist WEB-2086.

scientific article published on June 2006

Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele

scientific article

Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study

scientific article published on 18 May 2015

Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia

scientific article published on 26 December 2013

Inconsistencies in the association between the JAK2V617F mutation and PRV-1 over-expression among the chronic myeloproliferative diseases

scientific article published on 01 March 2006

Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms.

scientific article published on 16 June 2009

Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3.

scientific article

Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia

scientific article published on 01 January 2008

Internal tandem duplications of Flt3 gene (Flt3/ITD) predicts a poor post-remission outcome in adult patients with acute non-promyelocytic leukemia.

scientific article published in January 2004

JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib.

scientific article published in May 2015

MicroRNA expression profile in granulocytes from primary myelofibrosis patients.

scientific article

Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1).

scientific article published on 21 September 2006

Neutrophilic progression in a case of polycytemia vera mimicking chronic neutrophilic leukemia: clinical and molecular characterization

scientific article published on 23 October 2014

Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis.

scientific article

Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients.

scientific article

Recommendations for molecular testing in classical Ph1-neg myeloproliferative disorders-A consensus project of the Italian Society of Hematology

scientific article

Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.

scientific article

Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation.

scientific article

Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms

scientific article

The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients

scientific article published on 19 February 2014

Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis.

scientific article published on 16 October 2015

Variegation of the phenotype induced by the Gata1low mutation in mice of different genetic backgrounds

scientific article published on 18 August 2005

WEB-2086 and WEB-2170 trigger apoptosis in both ATRA-sensitive and -resistant promyelocytic leukemia cells and greatly enhance ATRA differentiation potential.

scientific article published on March 2005

List of works by Alessandro Pancrazzi

A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF- 1 in the development of myelofibrosis

A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction.

Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis

Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms

Anaemia characterises patients with myelofibrosis harbouring Mpl mutation.

B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis.

CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients

CXCR4-independent rescue of the myeloproliferative defect of the Gata1low myelofibrosis mouse model by Aplidin

Clonal architecture of JAK2V617F mutated cells during treatment with ruxolitinib.

Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group

Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM090

Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis

Growth inhibition and differentiation of human breast cancer cells by the PAFR antagonist WEB-2086.

Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele

Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study

Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia

Inconsistencies in the association between the JAK2V617F mutation and PRV-1 over-expression among the chronic myeloproliferative diseases

Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms.

Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3.

Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia

Internal tandem duplications of Flt3 gene (Flt3/ITD) predicts a poor post-remission outcome in adult patients with acute non-promyelocytic leukemia.

JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib.

MicroRNA expression profile in granulocytes from primary myelofibrosis patients.

Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1).

Neutrophilic progression in a case of polycytemia vera mimicking chronic neutrophilic leukemia: clinical and molecular characterization

Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis.

Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients.

Recommendations for molecular testing in classical Ph1-neg myeloproliferative disorders-A consensus project of the Italian Society of Hematology

Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.

Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation.

Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms

The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients

Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis.

Variegation of the phenotype induced by the Gata1low mutation in mice of different genetic backgrounds

WEB-2086 and WEB-2170 trigger apoptosis in both ATRA-sensitive and -resistant promyelocytic leukemia cells and greatly enhance ATRA differentiation potential.